Skip to main content
. 2020 Jan 27;12(2):101. doi: 10.3390/pharmaceutics12020101

Figure 2.

Figure 2

Molecular interaction network associated with development disorder, ophthalmic disease, organismal injury, and abnormalities assembled from retina proteins impacted by E2 given in eye drops to OVX rats. See explanation of shapes, colors and lines in the legend of Figure 1. Abbreviations: ALAD, aminolevulinate dehydratase; ATPase, adenosine triphosphatase; CRYAA/CRYAA2, α-crystallin A/A2; CRYBA1, CRYBA2, CRYBA4, CRYBB1, and CRYBB2, β-crystallin A1, A2, A4, B1 and B2; DNAJ32, DnaJ heat shock protein family (Hsp40) member B2; DR1, down regulator of transcription 1; GRIPA1, glutamate receptor-interacting protein associated protein 1; HGS, hepatocyte growth factor-regulated tyrosine kinase substrate; HSD17B12, hydroxysteroid 17-β dehydrogenase 12; HSP, heat shock protein; Hsp70, heat shock protein 70; HSPH1, heat shock protein family H (Hsp110) member 1; NSFL1C, N-ethylmaleimide-sensitive factor L1 cofactor; PSMB4, proteasome subunit-β 4; PSMC2, proteasome 26S subunit, non-ATPase 2; PSMD, proteasome 26S subunit, non-ATPase; PSMD4, PSMD9 and PSMD13, proteasome 26S subunit, non-ATPase 4, 9 and 13; RAD23B, nucleotide excision protein RAD23 homolog B; SCRN1, secernin 1; SUMO1, small ubiquitin-like modifier 1; TXNDC12, thioredoxin domain containing 12; UBA2, ubiquitin-like modifier activating enzyme 2; UBQLN1, ubiquilin 1.